
In a press release on Thursday morning, Danish biotech company Bavarian Nordic states that new preclinical trial data indicates that the firm's vaccine candidate against covid-19 also has the ability to induce a high number of neutralizing antibodies against covid variants and mutations.
"We are pleased to confirm the strong antibody response against emerging and more concerning variants of Sars-CoV2 for our covid-19 vaccine candidate," says Bavarian Nordic CEO Paul Chaplin the statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app